Showing session: reset
Developmental Therapeutics: Clinical Results of Novel Agents
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Introduction
Anthony El-Khoueiry
USC Norris Comprehensive Cancer Ctr., Los Angeles, CA, United States
- Free
- audio + slides
- Some slides withheld
Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors
Khanh T Do
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
Amy E Armstrong
Indiana University, Riley Hospital for Children, Indianapolis, IN, United States
- Free
- slides video
- audio + slides
- All slides included
A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2
Kim A Reiss Binder
University of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer
Kyle C Cuneo
University of Michigan, Ann Arbor, MI, United States
- Free
- slides video
- audio + slides
- All slides included
Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster
Olivera J Finn
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
- Permission not
granted for presentation
Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel
Rakesh Awasthi
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Free
- slides video
- audio + slides
- All slides included
TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center, Houston, TX, United States